Search Results
Your search for all items matches 34730 pages
Showing 24551 - 24600A Cancer Patient’s Harried Survivorship Story
There are approximately 14 million cancer survivors in the United States, a number that is steadily increasing, thanks to our advances in detection and treatment. However, surviving cancer can leave a host of physical, emotional, and financial hardships for years after diagnosis and treatment. In ...
A Hard Look at the Connection Between Germs and Mental Illness
The relationship between disease and microbes was first proposed in the 17th century, but the basic standards for proving that infection causes disease were not laid down until 1883, when the German bacteriologists Robert Koch and Friedrich Loeffler provided the first evidence of the processes...
A Doctor’s Prescription for a Long Life
Longevity is a common goal among humans. And like all things human, it is not distributed equally. According to world health data, Japan is number one on the longevity list; its 130 million citizens have a life expectancy of about 84.74 years. The sub-Saharan country of Chad is number 224, having ...
A Gene Hunter’s Advice on How to Take Control of Your Genetic Inheritance
Since the late 1970s, researchers have identified several gene mutations that are implicated in cancer. Many of these mutations are acquired during our lifetime, but, as we know, some are inherited in families. Identifying heritable cancer-causing genetic mutations is a double-edged sword,...
2016 Oncology Meetings
MARCH 2016 Methods in Clinical Research Workshop for Minority PhysiciansMarch 17-20 • Fort Lauderdale, FloridaFor more information:https://www.roswellpark.edu/education/diversity-clinical-research-workshop The 16th Multidisciplinary Management of Cancers: A Case-Based ApproachMarch 18-20 • Napa,...
A Drop of Blood
I was a third-year internal medicine resident, rotating through the oncology service, when I was asked to perform my first circumcision. My team was rounding on Tom, a 52-year-old gentleman currently receiving third-line treatment for metastatic esophageal cancer; we were discussing at length his...
A Fight to Remember
In 2006, one of my close friends, Robert O’Connor, won the mayoral race for my hometown of Pittsburgh, Pennsylvania. Everyone loved Robert, affectionately known as “Bob” and often referred to as “The People’s Mayor.” Bob was “Mr. Pittsburgh,” and it was his promise to reverse the city’s...
Actively Recruiting Clinical Trials Investigating Late Effects in Childhood Cancer Survivors
PILOT Study Title: Feasibility of Assessing Blood Pressure Remotely in Childhood Cancer Survivors (Pilot Study-Survivor) Study Type: Interventional/randomized/parallel assignment Study Sponsor and Collaborators: St. Jude Children’s Research Hospital Purpose: To evaluate a high blood pressure...
Benefiting From Mind-Body Therapy
My diagnosis of early-stage breast cancer at age 35 was a shock, also because I come from a family with no history of cancer. In disbelief, I was literally speechless—I lost my voice completely for several days. I grew up in the former Soviet Union and then in the newly independent Kyrgyzstan. My...
Expert Point of View: Carlos Arteaga, MD
Carlos Arteaga, MD, of Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, said, “Breast-conserving therapy is the right thing to do. This study will not change current practice guidelines. Mastectomy is generally reserved for larger tumors and those with multifocal disease. The study just...
Study Shows Breast-Conserving Therapy Beats Mastectomy, but Questions Remain
Breast-conserving therapy (lumpectomy plus radiation therapy) appears to improve 10-year overall survival for women with early breast cancer compared with mastectomy, according to a very large population-based study from the Netherlands.1 However, the study raises more questions than it answers,...
‘Know Your Tumor’ Program Aids Patients With Pancreatic Cancer
Patients with pancreatic cancer can obtain molecular tumor profiling through the Pancreatic Cancer Action Network’s Know Your TumorSM precision medicine initiative, a partnership with Perthera, a personalized medicine service company that facilitates the multi-omic profiling and generates the...
Expert Point of View: Wells Messersmith, MD
Wells Messersmith, MD, Professor and Head of Medical Oncology and Director of the Gastrointestinal Cancer Program, University of Colorado, Denver, discussed the two studies. Closer Look at STEAM Dr. Messersmith said the FOLFOXIRI (fluorouracil [5-FU], leucovorin, oxaliplatin, irinotecan) vs FOLFOX...
Studies Evaluate Bevacizumab-Containing Regimens in Metastatic Colorectal Cancer
Two trials reported at the 2016 Gastrointestinal Cancers Symposium evaluated bevacizumab (Avastin)-containing regimens in the first-line treatment of metastatic colorectal cancer and supported some, but not all, previous findings. The STEAM trial found some numerical differences but no...
The Time Is Now for the Worldwide Cancer Community to Be Proactive
The ASCO Post recently spoke with nationally recognized surgical oncologist Chandrakanth Are, MBBS, MBA, FRCS, FACS, Jerald L & Carolynn J. Varner Professor of Surgical Oncology & Global Health; Vice Chair of Education; and Program Director, General Surgery Residency, University of Nebraska ...
NCCN Awards 10 Grants for Provider Performance and Quality in Treatment of Metastatic Breast Cancer Initiatives
The National Comprehensive Cancer Network® (NCCN) Oncology Research Program (ORP), in collaboration with Pfizer Independent Grants for Learning & Change (IGLC), has awarded 10 grants for project proposals to develop and adopt evidence-based initiatives to improve patient care and outcomes in...
New High-Intensity Focused Ultrasound Advances Treatment for Prostate Cancer
For the estimated 220,000 men who will be diagnosed with prostate cancer this year, deciding on a method of treatment can be a challenge. Some with early-stage cancer pursue active surveillance, while others with more severe cancer immediately pursue surgery, including prostatectomy. Others fall...
Biomarkers in Prostate Cancer: PARP Inhibitors and Defects in DNA Repair
New data on molecular biomarkers in advanced prostate cancer are accumulating at a fast pace. The studies in this area can now be broadly grouped in two distinct areas—those that broadly relate to androgen signaling and those that relate to DNA-repair pathways. The Androgen-Signaling Pathway With...
PARP Inhibitor Olaparib Produces High Response Rate in Metastatic Prostate Cancer With DNA-Repair Defects
In the TOPARP-A phase II trial reported in The New England Journal of Medicine, Joaquin Mateo, MD, of the Institute of Cancer Research and The Royal Marsden in London, and colleagues, found that the PARP inhibitor olaparib (Lynparza) produced a high response rate in patients with previously treated ...
Minimal Residual Disease Identified by NPM1 Mutation Is a Powerful Marker for Poorer Outcome in Standard-Risk AML
In a study reported in The New England Journal of Medicine, Adam Ivey, MSc, from Guy’s Hospital, London, and colleagues found that a leukemia-specific marker consisting of mutation in the gene encoding nucleophosmin (NPM1) can be used to identify minimal residual disease in peripheral blood in...
Introduction of New Diagnostic Devices in Oncology: New Is Not Necessarily Better
“New!” “Improved!” “Throw out that old [fill in the blank] and go buy a new [fill in the blank]!” Sound familiar? The key to marketing is to convince customers that they need a product without which they had previously been quite happy. All too often, this strategy is accompanied by a caveat emptor ...
Potential Overdiagnosis of Contralateral Breast Cancer With Preoperative Breast MRI in Older Women With Breast Cancer
In an analysis of the Surveillance, Epidemiology, and End Results (SEER)-Medicare database reported in the Journal of Clinical Oncology, Shi-Yi Wang, MD, PhD, of Yale School of Public Health, and colleagues found that the use of preoperative magnetic resonance imaging (MRI) was associated with...
How Rehabilitation Services Provide Benefit for Patients With Spinal Metastases
The benefits of rehabilitation in traumatic spinal injuries are well established. Recently, studies have shown similarly positive results in cancer-related spinal injuries, indicating that rehabilitation can play a complementary role in the care management of this patient population....
Increased Travel Burden Decreases Likelihood of Receiving Radiation Therapy for Rectal Cancer Treatment
Increased travel distance to a cancer treatment facility negatively impacts the likelihood that patients with stage II/III rectal cancer will receive radiation therapy to treat their disease, according to a study analyzing 26,845 patient records from the National Cancer Data Base (NCDB) published...
Modified CAR T Cells Overcome Immune Suppression, Effective Against Solid Tumors in Preclinical Models
Adding a genetically engineered “switch receptor” to second-generation CAR T cells blocked PD-1–mediated immune suppression, and made the immunotherapy effective against solid tumors in preclinical models, according to a study published by Liu et al in Cancer Research....
Neratinib Improves Invasive Disease–Free Survival After Trastuzumab-Based Therapy in HER2-Positive Breast Cancer
Chan et al found that 1 year of treatment with the HER1, 2, and 4 tyrosine kinase inhibitor neratinib improved invasive disease–free survival vs placebo after trastuzumab (Herceptin)-based adjuvant therapy in patients with early-stage HER2-positive breast cancer, in the phase III ExteNET...
Poorer Outcome With BRAF and KRAS Mutations in Microsatellite-Stable but Not Microsatellite-Unstable Colon Cancer
In an analysis of the PETACC-8 trial reported by Taieb et al in JAMA Oncology, BRAF V600 and KRAS mutations were associated with shorter disease-free and overall survival in patients with microsatellite-stable colon cancer—but not in those with tumors with microsatellite instability—in...
Occult Metastasis on Immunohistochemistry May Affect Survival in Stage I NSCLC
Mature results of the Cancer and Leukemia Group B 9761/Alliance study, reported in the Journal of Clinical Oncology by Martin et al, indicate that occult metastases detected by immunohistochemistry in N2 lymph nodes may be associated with poorer overall survival after resection in clinical stage I...
Hypofractionated Radiotherapy Not Noninferior to Standard Radiotherapy in Late Genitourinary and Gastrointestinal Toxicity in Prostate Cancer
Hypofractionated radiotherapy was not noninferior to conventionally fractionated radiotherapy in late genitourinary and gastrointestinal toxicity in patients with prostate cancer in the Dutch phase III HYPRO trial. These findings were reported by Aluwini et al in The Lancet Oncology. An earlier...
Closing the Clinical Trial Gap for Adolescents and Young Adults With Cancer
Although overall survival rates for patients with cancer continue to soar—with 14.5 million cancer survivors today1—most of that gain is among pediatric and older adult patients. For adolescents and young adults with cancer—defined by the National Cancer Institute (NCI) as those in the 15- to...
Lauren Streicher, MD, Announced as Medical Director for Northwestern Medicine’s Upcoming Center for Sexual Health
Northwestern Medical Group recently announced that Lauren Streicher, MD, will be joining Northwestern Medicine in Chicago. Dr. Streicher is a clinical leader in gynecology, a published author, and a trusted medical contributor for many local and national media outlets. In her new role, Dr....
ASTRO Expands Its Advocacy and Government Relations Team With New Assistant Director
The American Society for Radiation Oncology (ASTRO) recently welcomed Stephanie Quinn as its Assistant Director of Congressional Relations, a key position on the Society’s government relations and advocacy team. As ASTRO’s chief liaison to Capitol Hill, Ms. Quinn will lead efforts to educate...
Geriatric Assessment of Transplant-Ineligible Older Adults With Multiple Myeloma: A Novel Approach in the Era of Novel Agents
Myeloma is a disease of aging, with a median age at diagnosis in the United States of 69 years.1 As the population ages, forecasts estimate that, within 20 years, 3 of every 4 people diagnosed with multiple myeloma in the United States will be between the ages of 64 and 84 years.2 In anticipation...
2016 ASH-AMFDP Scholars to Study Malaria, Immunotherapy for Hematologic Malignancies
The American Society of Hematology (ASH) is pleased to announce that Natasha Archer, MD, MPH, of Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, and Rayne Rouce, MD, of Baylor College of Medicine, have been selected to participate in the American Society of Hematology-Harold Amos...
Is This the Dawn of Cancer Biosimilars?
The Patient Protection and Affordable Care Act, signed into law in 2010, did more than make it possible for millions of Americans to afford health care; it also established an abbreviated approval pathway for biologic products that are “biosimilar” to, or shown to be “interchangeable” with, a U.S....
Obinutuzumab in Relapsed or Refractory Follicular Lymphoma
On February 26, 2016, obinutuzumab (Gazyva) was approved for use in combination with bendamustine (Bendeka, Treanda) followed by obinutuzumab monotherapy for treatment of patients with follicular lymphoma who have relapsed after or are refractory to a rituximab (Rituxan)-containing regimen.1,2...
Two Types of Asparaginase Compared in Newly Diagnosed Childhood Acute Lymphoblastic Leukemia
Intravenous pegylated (PEG) Escherichia coli (E coli) asparaginase was associated with similar toxicity and efficacy compared with intramuscular native E coli L-asparaginase in children with newly diagnosed acute lymphoblastic leukemia, according to the results of a phase III trial (DFCI 05-001).1 ...
Scandinavian Sarcoma Group Trial Shows Continued Benefit With 3 Years vs 1 Year of Adjuvant Imatinib in High-Risk GIST
As reported in the Journal of Clinical Oncology by Heikki Joensuu, MD, PhD, of the Comprehensive Cancer Center Helsinki, Finland, and colleagues, the second planned analysis in the Scandinavian Sarcoma Group XVIII/AIO trial showed a recurrence-free survival benefit and a continued overall survival ...
No Apparent Benefit of Long-Term Mifepristone in the Treatment of Unresectable Meningioma
In a phase III trial (SWOG S9005) reported in the Journal of Clinical Oncology,1 YongLi Ji, MD, PhD, and Claire Verschraegen, MD, of the University of Vermont Cancer Center; and colleagues found no benefit of treatment with the antiprogestin agent mifepristone vs placebo in patients with...
Study Finds Correlation Between Number of Drug Suppliers and Drug Shortages
Astudy published in the Journal of Oncology Practice1 found that individual drugs with fewer suppliers were associated with an increased likelihood of shortages compared to drugs with a large number of suppliers. The article titled, “Association between the Number of Suppliers for Critical...
Conquering Cancer With Dr. Kim
There are many different ways to treat cancer: surgery, radiation therapy, chemotherapy, and more, sometimes used alone and sometimes in combination. But, in certain circumstances, the best treatment option for a patient may not look much like treatment at all. Instead of attempting to eliminate...
ASCO University® Launches New Certificate Programs for Advanced Practitioners
The role of advanced practitioners in oncology is growing as the demand for team-based care increases—and with that growth comes a need for training materials specifically tailored to this group. ASCO University®, ASCO’s home for lifelong learning, has collaborated with the Association of Physician ...
Direct Your Patients to Cancer.Net for Patient-Friendly Videos
Check out some of the newest Cancer.Net patient-friendly videos produced by ASCO. New topics include an introduction to sarcoma, brain tumors, and managing the side effects of chemotherapy. These videos give people with cancer and their families and friends an additional option for receiving...
Join the Conversation Online at jgo.org
Journal of Global Oncology now offers readers the option to comment on any JGO article. Users can sign in through social media or a Disqus account and share their thoughts with the JGO community. All comments will be moderated by the journal to ensure they are constructive and relevant. Start a...
2016 Pre–Annual Meeting Educational Programs Feature Important Topics for Modern Cancer Care Providers
For oncology professionals looking to maximize their learning and networking opportunities, ASCO will be offering two types of Pre–Annual Meeting Educational Programs ahead of its 2016 Annual Meeting in Chicago this summer. Offered since 2012, Pre–Annual Meeting Seminars are a series of in-depth...
Palbociclib Combined With Fulvestrant in Advanced Breast Cancer Progressing After Endocrine Therapy
On February 19, 2016, palbociclib (Ibrance) was approved for use in combination with fulvestrant (Faslodex) for treatment of hormone receptor–positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy.1,2 In February 2015, palbociclib in...
Cancer Survivorship Research: Learning From the Past to Improve Future Outcomes
Soon after effective therapies for some childhood malignancies were first identified, early leaders in our field had concerns about what would happen to surviving patients as they aged. In 1975, Giulio D’Angio, MD, one of the founders of modern pediatric radiation oncology, presciently called for...
Reduction in Late Mortality in Childhood Cancer Survivors
In a study reported in The New England Journal of Medicine, Gregory T. Armstrong, MD, MSCE, of St. Jude Children’s Research Hospital, Memphis, and colleagues found that late mortality has decreased over time among 5-year survivors of childhood cancer in the Childhood Cancer Survivor Study cohort.1...
Two Fellows Selected for ASCO’s Inaugural Health Policy Fellowship Program
ASCO has announced the two physicians selected for its new Health Policy Fellowship, which kicked off this past October. Robert M. Daly, MD, and Steve Y. Lee, MD, will be the fellows for the inaugural class, which runs from July 1, 2016, to July 1, 2017. The program, aimed at oncologists in the...
Douglas A. Levine, MD, FACOG, FACS, Appointed Director of Gynecologic Oncology at NYU Langone
Douglas A. Levine, MD, FACOG, FACS, will join the faculty of NYU Langone Medical Center as Director of the Division of Gynecologic Oncology at its Laura and Isaac Perlmutter Cancer Center and the Department of Obstetrics and Gynecology, effective May 15, 2016. Dr. Levine brings an exceptional...
